Global Primary Immunodeficiency Therapeutic Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Primary Immunodeficiency Therapeutic market size was valued at US$ 522 million in 2024 and is forecast to a readjusted size of USD 755 million by 2031 with a CAGR of 5.5% during review period.
Primary immunodeficiencies are a group of different disorders in which part of the body"s immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Primary Immunodeficiency Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Primary Immunodeficiency Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Primary Immunodeficiency Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Primary Immunodeficiency Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols, Lupin Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Primary Immunodeficiency Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others
Market segment by Application
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
Market segment by players, this report covers
Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Primary Immunodeficiency Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Primary Immunodeficiency Therapeutic, with revenue, gross margin, and global market share of Primary Immunodeficiency Therapeutic from 2020 to 2025.
Chapter 3, the Primary Immunodeficiency Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Primary Immunodeficiency Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Primary Immunodeficiency Therapeutic.
Chapter 13, to describe Primary Immunodeficiency Therapeutic research findings and conclusion.
Primary immunodeficiencies are a group of different disorders in which part of the body"s immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Primary Immunodeficiency Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Primary Immunodeficiency Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Primary Immunodeficiency Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Primary Immunodeficiency Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Primary Immunodeficiency Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols, Lupin Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Primary Immunodeficiency Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others
Market segment by Application
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
Market segment by players, this report covers
Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Primary Immunodeficiency Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Primary Immunodeficiency Therapeutic, with revenue, gross margin, and global market share of Primary Immunodeficiency Therapeutic from 2020 to 2025.
Chapter 3, the Primary Immunodeficiency Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Primary Immunodeficiency Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Primary Immunodeficiency Therapeutic.
Chapter 13, to describe Primary Immunodeficiency Therapeutic research findings and conclusion.
Table of Contents
86 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
